Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Electronic Adverse Event Filing Could Be Phased In Over Four Years - FDA

Executive Summary

FDA is suggesting a four-year phase-in for mandatory electronic submissions to its adverse event reporting system in an advanced notice of proposed rule-making (ANPR) published in the Nov. 5 Federal Register.
Advertisement

Related Content

Adverse Event Reports Should Be 80% Electronic By Year End, FDA Hopes
Adverse Event Reports Should Be 80% Electronic By Year End, FDA Hopes
Electronic NDAs: Reviewer, Industry Training Is Focus For CDER Office
Electronic NDAs: Reviewer, Industry Training Is Focus For CDER Office
Advertisement
UsernamePublicRestriction

Register

PS033109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel